The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis

Kim, S.-J.; Lee, S.W.

doi:10.1016/j.crad.2019.06.022

Cited by 25 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, it is well established that 18F-Fluciclovine is highly useful in the detection of recurrent prostate cancer, when conventional bone scan and CT and/or MRI imaging are negative [29]. Our meta-analysis study showed promising results in terms of sensitivity and specificity of 18F-Fluciclovine PET/CT, as recently reported in other meta-analysis recently published [31][32][33]. High specificity values have been observed for preoperative LN staging (almost 100%); acceptable (although lower) pooled specificity (68%) was obtained for the detection of PCa recurrence in terms of local recurrence and nodal localization.…”

Section: Discussionsupporting

confidence: 78%

18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background: to explore the diagnostic accuracy of 18F-Fluciclovine positron-emission tomography (PET) in prostate cancer (PCa), considering both primary staging prior to radical therapy, biochemical recurrence, and advanced setting. Methods: A systematic web search through Embase and Medline was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies performed from 2011 to 2020 were evaluated. The terms used were “PET” or “positron emission tomography” or “positron emission tomography/computed tomography” or “PET/CT” or “positron emission tomography-computed tomography” or “PET-CT” and “Fluciclovine” or “FACBC” and “prostatic neoplasms” or “prostate cancer” or “prostate carcinoma”. Only studies reporting about true positive (TP), true negative (TN), false positive (FP) and false negative (FN) findings of 18F-fluciclovine PET were considered eligible. Results: Fifteen out of 283 studies, and 697 patients, were included in the final analysis. The pooled sensitivity for 18F-Fluciclovine PET/CT for diagnosis of primary PCa was 0.83 (95% CI: 0.80–0.86), the specificity of 0.77 (95% CI: 0.74–0.80). The pooled sensitivity for preoperative LN staging was 0.57 (95% CI: 0.39–0.73) and specificity of 0.99 (95% CI: 0.94–1.00). The pooled sensitivity for the overall detection of recurrence in relapsed patients was 0.68 (95% CI: 0.63–0.73), and specificity of 0.68 (95% CI: 0.60–0.75). Conclusion: This meta-analysis showed promising results in term of sensitivity and specificity for 18F-Fluciclovine PET/CT to stage the primary lesion and in the assessment of nodal metastases, and for the detection of PCa locations in the recurrent setting. However, the limited number of studies and the broad heterogeneity in the selected cohorts and in different investigation protocols are limitation affecting the strength of these results.

show abstract

Section: Discussionsupporting

confidence: 78%

18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In some meta-analyses, diagnostic accuracy of 18 F-FACBC PET/CT was reported as moderate: higher in the staging than restaging setting [ 8 , 32 , 33 , 34 , 35 , 36 ]. In the first meta-analysis by Ren et al [ 36 ], 18 F-FACBC PET/CT demonstrated a pooled sensitivity and pooled specificity of 87% and 66%, respectively, in detecting BR-PCa.…”

Section: Resultsmentioning

confidence: 99%

“…11 C-acetate PET/CT showed intermediate or low-accuracy values both in PCa staging and restaging setting [ 11 , 14 , 38 ]. 18 F-FACBC PET/CT showed good accuracy values, with better performance in the staging than in restaging setting [ 8 , 32 , 33 , 34 , 35 , 36 ]. High accuracy values of 18 F-NaF PET/CT emerged in the detection of bone metastases of patients with PCa [ 4 , 37 ].…”

Section: Discussionmentioning

confidence: 99%

“…Based on the meta-analysis by Kim et al [35], the pooled sensitivity for 18 F-FACBC PET or PET/CT for diagnosis of primary PCa was 87% and the pooled specificity 84%. For lymph nodal staging, the pooled sensitivity was 56% and the pooled specificity was 98%.…”

Section: F-facbc (Fluciclovine) Pet/ctmentioning

confidence: 99%

“…Different radiotracers for PET imaging have been proposed in recent years, such as radiolabeled choline (Cho) [ 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 ], prostate-specific membrane antigen (PSMA)-targeted agents [ 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 ], 18 F-fluciclovine (FACBC) [ 8 , 32 , 33 , 34 , 35 , 36 ], 18 F-fluoride (NaF) [ 4 , 37 ], 11 C-acetate [ 11 , 14 , 38 ], and 18 F-fluorodeoxyglucose ( 18 F-FDG) [ 11 , 14 ]. Moreover, different radioisotopes have been proposed to label some of these radiopharmaceuticals, such as to label Cho (e.g., 18 F, 11 C) and PSMA-targeted agents (e.g., 68 Ga, 18 F, 64 Cu).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses

Annunziata

Pizzuto

Treglia

2020

Cancers

View full text Add to dashboard Cite

A significant number of meta-analyses reporting data on the diagnostic performance of positron emission tomography (PET) in prostate cancer (PCa) is currently available in the literature. In particular, different PET radiopharmaceuticals were used for this purpose. The aim of this review is to summarize information retrieved by published meta-analyses on this topic. The first step included a systematic search of the literature (last search date: June 2020), screening two databases (PubMed/MEDLINE and Cochrane Library). This combination of key words was used: (A) “PET” OR “positron emission tomography” AND (B) “prostate” OR “prostatic” AND (C) meta-analysis. Only meta-analyses on Positron Emission Tomography/Computed Tomography (PET/CT) or Positron Emission Tomography/Magnetic Resonance (PET/MR) in PCa were selected. We have summarized the diagnostic performance of PET imaging in PCa, taking into account 39 meta-analyses published in the literature. Evidence-based data showed the good diagnostic performance of PET/CT with several radiopharmaceuticals, including prostate-specific membrane antigen (PSMA)-targeted agents, radiolabeled choline, fluciclovine, and fluoride in restaging and staging settings. Less evidence-based data were available for PET/MR with different radiotracers. More prospective multicentric studies and cost-effectiveness analyses are warranted.

show abstract

Correlative Approach to Prostate Imaging

Kooraki¹,

Jadvar²

2023

Radiology‐Nuclear Medicine Diagnostic Imaging

View full text Add to dashboard Cite

The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis

Cited by 25 publications

References 33 publications

18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis

18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis

Diagnostic Performance of PET Imaging Using Different Radiopharmaceuticals in Prostate Cancer According to Published Meta-Analyses

Correlative Approach to Prostate Imaging

Contact Info

Product

Resources

About